- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.03. | EXTRAWELL PHAR (00858): POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 28 MARCH 2025 | - | HKEx | ||
| 13.03. | EXTRAWELL PHAR (00858): SUPPLEMENTAL ANNOUNCEMENT, PROPOSED APPOINTMENT OF AUDITOR, NOTICE OF SPECIAL GENERAL MEETING | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF CIRCULAR CONTAINING NOTICE OF SPECIAL ... | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF CIRCULAR CONTAINING NOTICE OF SPECIAL ... | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): NOTICE OF SPECIAL GENERAL MEETING | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): FORM OF PROXY FOR SPECIAL GENERAL MEETING TO BE HELD ON FRIDAY, 28 MARCH 2025 AT 11:00 A.M. | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): PROPOSED APPOINTMENT OF AUDITOR AND NOTICE OF SPECIAL GENERAL MEETING | - | HKEx | ||
| 07.03. | EXTRAWELL PHAR (00858): PROPOSED APPOINTMENT OF AUDITOR | 1 | HKEx | ||
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 17.12.24 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2024/25 | 1 | HKEx | ||
| 17.12.24 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2024/25 | - | HKEx | ||
| 17.12.24 | EXTRAWELL PHAR (00858): INTERIM REPORT 2024/25 | - | HKEx |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 30,650 | +0,46 % | Ionis Pharmaceuticals, Inc.: Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. | - Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world - - Ionis will continue to independently commercialize TRYNGOLZA (olezarsen)... ► Artikel lesen | |
| CSPC PHARMA | 0,988 | +1,58 % | Dividendenbekanntmachungen (04.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADESSO SE DE000A0Z23Q5 - 0,75 EUR AGEAS SA/NV BE0974264930 - 2 EUR AIR LEASE CORPORATION US00912X3026 0,22 USD 0,1934 EUR ANALOG... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,430 | +1,42 % | SELLAS Life Sciences Group, Inc.: SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting | - ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer - - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,085 | -1,01 % | JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory | ||
| MADRIGAL PHARMACEUTICALS | 243,70 | -0,12 % | Citizens JMP behält positive Einschätzung für Madrigal-Aktie bei | ||
| CATALYST PHARMACEUTICALS | 22,750 | +0,22 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer | CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,061 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | ||
| OPUS GENETICS | 0,930 | -0,11 % | XFRA R3X1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILOPUS GENETICS DL-... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets | Northvale, New Jersey--(Newsfile Corp. - April 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,019 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 10.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.02.2025ISIN NameES0105015012 LAR... ► Artikel lesen | |
| SAVARA | 2,200 | +2,80 % | Savara wählt Vorstandsmitglieder und genehmigt Vorschläge bei Jahresversammlung | ||
| GALECTIN THERAPEUTICS | 1,130 | -2,59 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 1,130 | -1,74 % | Biodexa Pharmaceuticals PLC: Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes | June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (Nasdaq: BDRX), a clinical stage... ► Artikel lesen | |
| SCICLONE PHARMACEUTICALS | - | - | Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone | TOKYO, Feb 28, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has entered into a license agreement granting the exclusive development and distribution rights for the fibroblast... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 0,590 | 0,00 % | NovaBay Pharmaceuticals, Inc. - 10-Q, Quarterly Report |
Das Unternehmen EXTRAWELL PHARMACEUTICAL HOLDINGS LTD kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXTRAWELL PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.